Drugs / CHS-114
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06657144 | Apr 2025 → Jan 2028 expected | metastatic neoplasm | Coherus Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05635643 | Dec 2022 → Sep 2026 expected | head and neck squamous cell carcinoma | Coherus Oncology, Inc. | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05635643 ↗ |
| Known as | Tagmokitug | “CHS-114 (Tagmokitug)” NCT06657144 ↗ |
| Action | Deplete | “CHS-114 selectively binds human CCR8 and potently kills CCR8 expressing cells by inducing antibody-dependent cellular cytotoxicity” PMID 41423415 ↗ May 2026 |
| Modality | Monoclonal antibody | “CHS-114 is a highly selective, afucosylated human anti-CCR8 monoclonal antibody” PMID 41423415 ↗ May 2026 |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT06657144 ↗ |
| Target | CCR8 | “CHS-114 selectively binds human CCR8” PMID 41423415 ↗ May 2026 |